2-fluoro-4-(1-oxo-2-(2-(pyrrolidin-1-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzoyl chloride | 1363047-41-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 2-fluoro-4-(1-oxo-2-(2-(pyrrolidin-1-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzoyl chloride
• CAS: 1363047-41-9
• 化学式: C₂₂H₂₂ClFN₂O₂
• 分子量: 400.88
• InChiKey: OWNNIRNNUXIXPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.97
• 重原子数：
  28.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  40.62
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  四氢吡咯 、 2-fluoro-4-(1-oxo-2-(2-(pyrrolidin-1-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzoyl chloride 在 盐酸 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 水 为溶剂， 反应 1.0h， 以59%的产率得到6-[3-fluoro-4-(pyrrolidin-1-ylcarbonyl)phenyl]-2-(2-pyrrolidin-1-ylethyl)-3,4-dihydroisoquinolin-1(2H)-one hydrochloride
  参考文献：
  名称：

  2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one Derivatives as Potent and Selective Histamine-3 Receptor Antagonists

  摘要：

  On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a new class of 2-(pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives (3-50) were synthesized and evaluated as potent H-3 receptor antagonists. In particular, compound 39 exhibited potent in vitro binding and functional activities at the H-3 receptor, good selectivities against other neurotransmitter receptors and ion channels, acceptable pharmacokinetic properties, and a favorable in vivo profile.

  DOI：

  10.1021/jm300011d
• 作为产物：
  描述：

  在 氯化亚砜 、 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 2-fluoro-4-(1-oxo-2-(2-(pyrrolidin-1-yl)ethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)benzoyl chloride
  参考文献：
  名称：

  2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one Derivatives as Potent and Selective Histamine-3 Receptor Antagonists

  摘要：

  On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a new class of 2-(pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives (3-50) were synthesized and evaluated as potent H-3 receptor antagonists. In particular, compound 39 exhibited potent in vitro binding and functional activities at the H-3 receptor, good selectivities against other neurotransmitter receptors and ion channels, acceptable pharmacokinetic properties, and a favorable in vivo profile.

  DOI：

  10.1021/jm300011d